期刊文献+

“Liverscore”is predictive of both liver fi brosis and activity in chronic hepatitis C

"Liverscore"is predictive of both liver fi brosis and activity in chronic hepatitis C
在线阅读 下载PDF
导出
摘要 AIM:To formulate a noninvasive index predictive of se-verity of liver f ibrosis and activity in chronic hepatitis C.METHODS:This cross sectional study was conducted on polymerase chain reaction positive,treatment nave patients.Fibrosis was staged on a f ive point scale from F0-F4 and activity was graded on a four point scale from A0-A3,according to the METAVIR system.Patients were divided into two overall severity groups,minimal disease(< F2 and < A2)and signif icant disease(≥ F2 or ≥ A2).Eleven markers were measured in blood.Sta-tistically,the primary outcome variable was identif ica-tion of minimal and signif icant overall disease.Indices were formulated using β regression values of different combinations of nine statistically significant factors.Diagnostic performance of these indices was assessed through receiver-operating characteristic curve analysis.RESULTS:A total of 98 patients were included and of these 46 had an overall clinically significant disease.Our f inal six marker index,Liverscore for Hepatitis C,consisted of age,alanine transaminase,gamma-gluta-myl transpeptidase,apolipoprotein A-1,alpha-2 macro-globulin and hyaluronic acid.The area under the curve was found to be 0.813.On a 0-1 scale,negative predic-tive value at a cutoff level of ≤ 0.40 was 83%,while positive predictive value at ≥ 0.80 remained 89%.Al-together,61% of the patients had these discriminative scores.CONCLUSION:This index is discriminative of minimal and significant overall liver disease in a majority of chronic hepatitis C patients and can help in clinical de-cision making. AIM:To formulate a noninvasive index predictive of se-verity of liver f ibrosis and activity in chronic hepatitis C.METHODS:This cross sectional study was conducted on polymerase chain reaction positive,treatment nave patients.Fibrosis was staged on a f ive point scale from F0-F4 and activity was graded on a four point scale from A0-A3,according to the METAVIR system.Patients were divided into two overall severity groups,minimal disease(〈 F2 and 〈 A2)and signif icant disease(≥ F2 or ≥ A2).Eleven markers were measured in blood.Sta-tistically,the primary outcome variable was identif ica-tion of minimal and signif icant overall disease.Indices were formulated using β regression values of different combinations of nine statistically significant factors.Diagnostic performance of these indices was assessed through receiver-operating characteristic curve analysis.RESULTS:A total of 98 patients were included and of these 46 had an overall clinically significant disease.Our f inal six marker index,Liverscore for Hepatitis C,consisted of age,alanine transaminase,gamma-gluta-myl transpeptidase,apolipoprotein A-1,alpha-2 macro-globulin and hyaluronic acid.The area under the curve was found to be 0.813.On a 0-1 scale,negative predic-tive value at a cutoff level of ≤ 0.40 was 83%,while positive predictive value at ≥ 0.80 remained 89%.Al-together,61% of the patients had these discriminative scores.CONCLUSION:This index is discriminative of minimal and significant overall liver disease in a majority of chronic hepatitis C patients and can help in clinical de-cision making.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第41期4607-4613,共7页 世界胃肠病学杂志(英文版)
基金 Supported by Ziauddin University,Karachi and Pakistan Medical Research Council,Islamabad
关键词 Chronic hepatitis C Staging and grading Liver fibrosis and activity Noninvasive assessment Liverscore 丙型肝炎 指标预测 慢性 载脂蛋白A-1 科幻 聚合酶链反应 曲线分析 谷丙转氨酶
  • 相关文献

参考文献32

  • 1Zeremski M, Petrovic LM, Talal AH. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 2007; 14:675-687.
  • 2Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3:47-52.
  • 3Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
  • 4Idrees M, Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroentero12009; 9:5.
  • 5Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
  • 6Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol 2003; 38 Suppl 1:S38-S53.
  • 7Pakistan Medical Research Council. National survey on prevalence of hepatitis B & C in general population of Pakistan - 2008. Available from: URL: http://www.pmrc.org. pk/hepatitisbc.htm.
  • 8Human Development Report 2009. Overcoming barriers: Human mobility and development. United Nations Development Program. Available from: URL: http://www. un.org/esa/population/meetings/eighthcoord2009/ UNDP_OHDR_Klugmann.pdf.
  • 9Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroentero12000; 14:543-548.
  • 10Reiss G, Keeffe EB. Role of liver biopsy in the management of chronic liver disease: selective rather than routine. Rev Gastroenterol Disord 2005; 5:195-205.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部